We are live on ! Find out more
PG

Prostatis Group Portfolio holdings

AUM $391M
1-Year Est. Return 20.37%
This Fund
S&P 500
This Quarter Est. Return
+8.8%
1 Year Est. Return
+20.37%
3 Year Est. Return
+56.13%
5 Year Est. Return
+74.88%
10 Year Est. Return
AUM
$163M
AUM Growth
-$4.28M
Cap. Flow
-$16.1M
Cap. Flow %
-9.88%
Top 10 Hldgs %
47.02%
Holding
102
New
6
Increased
29
Reduced
52
Closed
12
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
XLY icon
101
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
$22.3B
-32,612
Closed -$2.93M
FFTI
102
DELISTED
FormulaFolios Tactical Income ETF
FFTI
-11,357
Closed -$273K

Similar funds

Prostatis Group's Q4 2021 Portfolio in Review

As of Q4 2021, Prostatis Group held 102 positions worth $163M, down 2.6% from $167M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Prostatis Group withdrew a net $16.1M in Q4 2021, closing 12 positions and reducing 52 holdings. Its most notable exit was iShares ESG Aware MSCI EAFE ETF, an estimated $5.04M position sold in full.

By sector, the portfolio is most concentrated in Technology at 6.1% of assets, up from 5.4% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Prostatis Group opened a new position in State Street Materials Select Sector SPDR ETF worth $3.53M.

  • Prostatis Group's largest Q4 2021 buy was State Street Materials Select Sector SPDR ETF: 77,820 shares worth $3.53M.
  • Prostatis Group added most to JPMorgan Chase in Q4 2021, an estimated $1.49M increase.
  • Prostatis Group's biggest Q4 2021 reduction was State Street SPDR S&P 1500 Value Tilt ETF, cutting an estimated $4.31M.
  • Prostatis Group fully exited iShares ESG Aware MSCI EAFE ETF in Q4 2021, selling an estimated $5.04M.
  • Prostatis Group's ten largest holdings make up 47% of its $163M portfolio in Q4 2021.
  • Prostatis Group opened 6 new positions and closed 12 in Q4 2021.
  • Prostatis Group's portfolio value fell 2.6% quarter-over-quarter to $163M.

Based on Prostatis Group's 13F filing for Q4 2021, filed 23 Mar 2023.